DERMABET Drug Patent Profile
✉ Email this page to a colleague
When do Dermabet patents expire, and when can generic versions of Dermabet launch?
Dermabet is a drug marketed by Taro and is included in one NDA.
The generic ingredient in DERMABET is betamethasone valerate. There are sixty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dermabet
A generic version of DERMABET was approved as betamethasone valerate by FOUGERA PHARMS INC on August 31st, 1983.
Summary for DERMABET
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 64 |
Patent Applications: | 5,145 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DERMABET at DailyMed |
Pharmacology for DERMABET
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for DERMABET
US Patents and Regulatory Information for DERMABET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taro | DERMABET | betamethasone valerate | CREAM;TOPICAL | 072041-001 | Jan 6, 1988 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |